In addition, MALAT1-high patients in the TCGA-PRAD cohort showed higher chances of relapse compared with the MALAT1-low group (P = 0.0013, Fig. 1F), suggesting that MALAT1 levels could also predict the likelihood of disease recurrence. Here, MALAT1 is linked to prostate adenocarcinoma.